ArticleJournal of nature and science2017
Refractory versus resistant hypertension: Novel distinctive phenotypes.
Article in Journal of nature and science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis.Current hypertension reports · 2022Pooled it
- Prevalence and clinical profile of refractory hypertension in a large cohort of patients with resistant hypertension.Journal of human hypertension · 2021Article
- Refractory hypertension: what do we know so far?Journal of human hypertension · 2021Article
- Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort.Hypertension (Dallas, Tex. : 1979) · 2021Article
- Clinical Characteristics of Resistant vs. Refractory Hypertension in a Population of Hypertensive Afrodescendants.Arquivos brasileiros de cardiologia · 2020Article
- Conceptualization of Heterogeneity of Chronic Diseases and Atherosclerosis as a Pathway to Precision Medicine: Endophenotype, Endotype, and Residual Cardiovascular Risk.International journal of chronic diseases · 2020Review
- Effects of different ablation points of renal denervation on the efficacy of resistant hypertension.PeerJ · 2020Article
- Resistant/Refractory Hypertension and Sleep Apnoea: Current Knowledge and Future Challenges.Journal of clinical medicine · 2019Review
- The Use of Neuromodulation for Symptom Management.Brain sciences · 2019Review
- Resistant Hypertension Updated Guidelines.Current cardiology reports · 2019Review
- The Potential Role of Obstructive Sleep Apnoea in Refractory Hypertension.Current hypertension reports · 2019Review
- Potential Deep Brain Stimulation Targets for the Management of Refractory Hypertension.Frontiers in neuroscience · 2019Review
- Mechanism of Thiazide Diuretic Arterial Pressure Reduction: The Search Continues.Frontiers in pharmacology · 2019Review
- [Therapy-resistant and therapy-refractory arterial hypertension].Der Internist · 2018Article
- Refractory hypertension focus on nighttime blood pressure and nondipping.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Resistant and refractory hypertension: two sides of the same disease?Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Resistant hypertension (RHTN) is relatively common with an estimated prevalence of 10-20% of treated hypertensive patients. It is defined as blood pressure (BP) >140/90 mmHg treated with ≥3 antihypertensive medications, including a diuretic, if tolerated. Refractory hypertension is a novel phenotype of severe antihypertensive treatment failure. The proposed definition for refractory hypertension, i.e. BP >140/90 mmHg with use of ≥5 different antihypertensive medications, including a diuretic
Indexed as
Identifiers
29034321PMC5640321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.